Drugs

Sunovion Drug Gets FDA Nod for Treating Parkinson's “Off” Episodes

10 days ago   |   By Xconomy

The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson's disease, giving patients a new way to take an old drug. The Sunovion product, Kynmobi, is a formulation of apomorphine hydrochloride, a drug that treats “off” episodes experienced by Parkinson's patients. These are times when the standard of care drug, levodopa, wears off and tremors, stiffness, and other symptoms return. Apomorphine can be administered in several different ways. The Sunovion product is the first sublingual formulation of apomorphine approved by the FDA. The FDA decision for Kynmobi comes 16...
Read more ...

 


Search by Tags

   Drugs      Drug      Pharmaceuticals      Pharmaceutical      Boston      Boston blog main      Boston top stories      National blog main      New York blog main      New York top stories      Acorda Pharmaceuticals      Apomorphine      Biotech      Clinical trials      Life Sciences      Parkinson's Disease      Safinamide      Sunovion Pharmaceuticals      SuperNus Pharmaceuticals      US WorldMeds  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

104714 Patient Navigator - Contract Appointment

MEDICINE/Infectious Diseases Salary commensurate with qualifications and experienceFiling Deadline: Mon 6/15/2020... Read more ...

Regeneron boosts Intellia CRISPR pact with bleeding disorder focus, cash boost

Regeneron boosts Intellia CRISPR pact with bleeding disorder focus, cash boost badams Mon, 06/01/2020 - 07:56 Read more ...

AbbVie pens cancer pact with U.S.-China biotech Jacobio

AbbVie pens cancer pact with U.S.-China biotech Jacobio badams Mon, 06/01/2020 - 07:28 Read more ...

Biotech IPO bonanza: Legend's $350M offering as Repare, Forma get in on the...

Biotech IPO bonanza: Legend's $350M offering as Repare, Forma get in on the action badams Mon, 06/01/2020 - 06:40 Read more ...

How a new biotech rule will foster distrust with the public and impede...

In May, federal regulators finalized a new biotechnology policy that will bring sweeping changes to the U.S. food system. Dubbed "SECURE," the rule revises U.S. Department of... Read more ...

FloChiP, a new tool optimizing gene-regulation studies

In the cell, proteins often interact directly with DNA to regulate and influence the expression of genes. For this to happen, proteins need to travel into the cell's nucleus... Read more ...

Researchers control cattle microbiomes to reduce methane and greenhouse gases

Ben-Gurion University of the Negev researchers have learned to control the microbiome of cattle for the first time which could inhibit their methane production, and therefore... Read more ...

Researchers develop biotechnological process for jasmonic acid production

Plants produce the hormone jasmonic acid as a defense response when challenged, making their leaves taste bad to predators. Biologists want to determine whether biological... Read more ...

Gossamer Bio Announces Participation in Upcoming Investor Conferences

SAN DIEGO--- $GOSS-Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease... Read more ...

DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of...

SAN DIEGO, June 1, 2020 /PRNewswire/ - DelMar Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today... Read more ...